Navigating the evolving therapeutic landscape in advanced prostate cancer (Q39173425)

9 September 2017

title

Navigating the evolving therapeutic landscape in advanced prostate cancer (English)

1 reference

9 September 2017

1 reference

E David Crawford

1

1 reference

9 September 2017

Daniel Petrylak

series ordinal

2

1 reference

9 September 2017

Oliver Sartor

series ordinal

3

1 reference

9 September 2017

publication date

7 March 2017

1 reference

9 September 2017

1 reference

9 September 2017

volume

35S

1 reference

9 September 2017

page(s)

S1-S13

1 reference

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Characterising the castration-resistant prostate cancer population: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

(68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Challenges and recommendations for early identification of metastatic disease in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Abiraterone in metastatic prostate cancer without previous chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Increased survival with enzalutamide in prostate cancer after chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Enzalutamide in metastatic prostate cancer before chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Sequencing of agents in castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Expression of Androgen Receptor Splice Variants in Prostate Cancer Bone Metastases is Associated with Castration-Resistance and Short Survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Plasma AR and abiraterone-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Genomic Alterations in Cell-Free DNA and Enzalutamide Resistance in Castration-Resistant Prostate Cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Integrative clinical genomics of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

Biallelic Inactivation of BRCA2 in Platinum-sensitive Metastatic Castration-resistant Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2017.01.020

10.1016/J.UROLONC.2017.01.020

7 January 2021

Identifiers

DOI

1 reference

9 September 2017

1 reference